CONFERENCE COVERAGE
European Committee for Treatment and Research in Multiple Sclerosis
Annual Meeting
- Ponesimod Promising for MRI Outcomes in Relapsing MS
- Extended-Release Amantadine Improves Walking Speed in Patients With MS
- Effects of Amiloride, Fluoxetine, Riluzole on Secondary Progressive MS
- CSF UCH-L1 Biomarker Predicts MS Long-Term Disease Progression
- Eculizumab Reduces Risk of Relapse in NMOSD
- Ozanimod May Be a Safe Long-Term Treatment for Relapsing MS
- SSRIs May Improve Response to First-Line DMT in Relapsing-Remitting MS
- Benefits of Remote Digital Neurological Assessment in MS
- HTN Onset Earlier in Those With MS Born After 1965
- Efficacy of Ofatumumab Greater than Teriflunomide in Early Relapsing MS
- DMTs Most Effective Among Certain Subgroups of Individuals With MS
- Improvements Are Needed to Measure Impact of Pediatric MS
Latest Tweets
Follow
@NeuroAdvisor
Conference Coverage from
